Deals
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.
Secarna Pharmaceuticals, a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide therapies to address challenging or previously undruggable targets, announced that the Company has completed a financing round, which was open only to existing investors.
Expedeon AG announces the signing of an agreement with Abcam plc, Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million.
The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.
Novartis said the acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.
Generates over USD 1 million in sales through new POCare platform
Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development
The good performance we saw in the second quarter has continued and further improved.
The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company.
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs